121 related articles for article (PubMed ID: 38225880)
21. Is Preoperative Type and Screen High-value Care? A Cost-effectiveness Analysis of Performing Preoperative Type and Screen Prior to Urogynecological Surgery.
Husk KE; Wang R; Rogers RG; Harvie HS
Int Urogynecol J; 2024 Apr; 35(4):781-791. PubMed ID: 38240801
[TBL] [Abstract][Full Text] [Related]
22. Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.
Tan C; Peng L; Zeng X; Li J; Wan X; Chen G; Yi L; Luo X; Zhao Z
PLoS One; 2013; 8(12):e83396. PubMed ID: 24340099
[TBL] [Abstract][Full Text] [Related]
23. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
24. A cost-effectiveness analysis of adjuvant chemoradiotherapy for resected gastric cancer.
Wang SJ; Fuller CD; Choi M; Thomas CR
Gastrointest Cancer Res; 2008 Mar; 2(2):57-63. PubMed ID: 19259297
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.
Lim SL; Havrilesky LJ; Habib AS; Secord AA
Gynecol Oncol; 2019 May; 153(2):376-380. PubMed ID: 30718126
[TBL] [Abstract][Full Text] [Related]
26. Economic Analysis of Neoadjuvant Chemotherapy Versus Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer Using an Aggressive Surgical Paradigm.
Cole AL; Barber EL; Gogate A; Tran AQ; Wheeler SB
Int J Gynecol Cancer; 2018 Jul; 28(6):1077-1084. PubMed ID: 29683880
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
28. Indwelling Pleural Catheter Drainage Strategy for Malignant Effusion: A Cost-Effectiveness Analysis.
Shafiq M; Simkovich S; Hossen S; Feller-Kopman DJ
Ann Am Thorac Soc; 2020 Jun; 17(6):746-753. PubMed ID: 32125880
[No Abstract] [Full Text] [Related]
29. Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer.
Meng M; Liu X; Liang X; Chen X; Li Y
Medicine (Baltimore); 2024 Apr; 103(16):e37836. PubMed ID: 38640325
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF.
van Heesch MM; van Asselt AD; Evers JL; van der Hoeven MA; Dumoulin JC; van Beijsterveldt CE; Bonsel GJ; Dykgraaf RH; van Goudoever JB; Koopman-Esseboom C; Nelen WL; Steiner K; Tamminga P; Tonch N; Torrance HL; Dirksen CD
Hum Reprod; 2016 Nov; 31(11):2527-2540. PubMed ID: 27907897
[TBL] [Abstract][Full Text] [Related]
31. Tranexamic acid in the routine treatment of postpartum hemorrhage in the United States: a cost-effectiveness analysis.
Sudhof LS; Shainker SA; Einerson BD
Am J Obstet Gynecol; 2019 Sep; 221(3):275.e1-275.e12. PubMed ID: 31226298
[TBL] [Abstract][Full Text] [Related]
32. Microdiscectomy Is More Cost-effective Than a 6-Month Nonsurgical Care Regimen for Chronic Radiculopathy.
Glennie RA; Urquhart JC; Koto P; Rasoulinejad P; Taylor D; Sequeira K; Miller T; Watson J; Rosedale R; Bailey SI; Gurr KR; Siddiqi F; Bailey CS
Clin Orthop Relat Res; 2022 Mar; 480(3):574-584. PubMed ID: 34597280
[TBL] [Abstract][Full Text] [Related]
33. Seven-year cost-effectiveness of ProDisc-C total disc replacement: results from investigational device exemption and post-approval studies.
Radcliff K; Lerner J; Yang C; Bernard T; Zigler JE
J Neurosurg Spine; 2016 May; 24(5):760-8. PubMed ID: 26824587
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States.
Wang J; Chmielowski B; Pellissier J; Xu R; Stevinson K; Liu FX
J Manag Care Spec Pharm; 2017 Feb; 23(2):184-194. PubMed ID: 28125365
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Polyzoi M; Sandhu H; Maervoet J; Yuan Y; Chaudhary MA; Varol N; Lee A; Dale P; Jones C; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):660-668. PubMed ID: 35658806
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness analysis of hemiarthroplasty and total shoulder arthroplasty.
Mather RC; Watters TS; Orlando LA; Bolognesi MP; Moorman CT
J Shoulder Elbow Surg; 2010 Apr; 19(3):325-34. PubMed ID: 20303459
[TBL] [Abstract][Full Text] [Related]
37. The Cost-Effectiveness of Bimodal Stimulation Compared to Unilateral and Bilateral Cochlear Implant Use in Adults with Bilateral Severe to Profound Deafness.
Theriou C; Fielden CA; Kitterick PT
Ear Hear; 2019; 40(6):1425-1436. PubMed ID: 30998548
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.
Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD
J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711
[TBL] [Abstract][Full Text] [Related]
39. Cost-Effectiveness Analysis of Open Versus Endovascular Revascularization for Chronic Mesenteric Ischemia.
Patel RJ; Cui C; Khan MA; Willie-Permor D; Malas MB
Ann Vasc Surg; 2023 Aug; 94():347-355. PubMed ID: 36878356
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of Total Neoadjuvant Therapy With Short-Course Radiotherapy for Resectable Locally Advanced Rectal Cancer.
Chin RI; Otegbeye EE; Kang KH; Chang SH; McHenry S; Roy A; Chapman WC; Henke LE; Badiyan SN; Pedersen K; Tan BR; Glasgow SC; Mutch MG; Samson PP; Kim H
JAMA Netw Open; 2022 Feb; 5(2):e2146312. PubMed ID: 35103791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
